Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea



Status:Completed
Conditions:Infectious Disease, Gastrointestinal
Therapuetic Areas:Gastroenterology, Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:9/13/2018
Start Date:August 2013
End Date:July 2014

Use our guide to learn which trials are right for you!

A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study

This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as
a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the
primary symptom of recurrent Clostridium difficile infection. All eligible subjects will
receive RBX2660.

This is the first study of a microbiota suspension derived from intestinal microbes. The
primary assessments for this open label, multi-center study are (i) occurrence of
product-related adverse events and (ii) resolution of CDAD at 56 days after administration of
RBX2660. Subjects will also be assessed for time to CDAD recurrence, quality of life changes,
and number of hospitalizations and length of stay for recurrent CDAD. Study visits will be at
7, 30, and 60 days after RBX2660 administration with additional follow-up at 3 and 6 months
post treatment. Patients who have had at least two recurrences of CDAD after a primary
episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or
have had at least two episodes of severe CDAD resulting in hospitalization may be eligible
for the study.

Inclusion Criteria:

- ≥ 18 years

- Medical record documentation of CDAD either: a) at least two recurrences after a
primary episode and have completed at least two rounds of standard-of-care oral
antibiotic therapy or b) have had at least two episodes of severe CDAD resulting in
hospitalization.

- Willing and able to have an enema(s).

- Already taking or will start a course of oral antibiotics for CDAD symptoms for 10-14
days, including at least seven days of oral vancomycin.

- Willing and able to complete the required subject diary.

Exclusion Criteria:

- Continued (uncontrolled) CDAD after completing a 10-14 day course of oral antibiotics.

- Requires antibiotic therapy for a condition other than CDAD.

- Previous fecal transplant prior to study enrollment.

- History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's
disease, or microscopic colitis.

- History of irritable bowel syndrome (IBS).

- History of chronic diarrhea.

- History of celiac disease.

- History of cirrhosis of the liver or ascites.

- Disease symptoms caused by a confirmed intestinal pathogen other than Clostridium
difficile.

- Has a colostomy.

- Intraabdominal surgery within the last 60 days.

- Evidence of active, severe colitis.

- History of short gut syndrome or motility disorders.

- Requires the regular use of medications that affect bowel motility (e.g.,
metoclopramide, narcotics, loperamide).

- Planned therapy in the next 3 months that may cause diarrhea (e.g., chemotherapy).

- Planned surgery requiring perioperative antibiotics within 6 months of study
enrollment.

- Life expectancy of < 12 months.

- Compromised immune system, e.g., HIV infection (any CD4 count); AIDS-defining
diagnosis or CD4 <200/mm3; inherited/primary immune disorders; immunodeficient or
immunosuppressed due to a medical condition or medication; current or recent (< 90
days) treatment with chemotherapy; or current or recent (< 90 days) treatment with
immunosuppressant medications.

- Taking steroids (≥ 20 mg a day) or is expected to be on steroids for more than 30 days
after enrollment.

- Neutropenia (white blood cell count <1000 cells/µL).
We found this trial at
13
sites
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
4800 Belfort Rd # 2
Jacksonville, Florida 32256
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Chevy Chase, Maryland 20815
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Fargo, North Dakota 58122
?
mi
from
Fargo, ND
Click here to add this to my saved trials
New Orleans, Louisiana 70121
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phoenix, Arizona 85054
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials